CN102838617A - Polymorph and pharmaceutical composition of (S)-2-(2- nicotinoyloxyjatropha-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorphenyl)-methyl acetate - Google Patents
Polymorph and pharmaceutical composition of (S)-2-(2- nicotinoyloxyjatropha-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorphenyl)-methyl acetate Download PDFInfo
- Publication number
- CN102838617A CN102838617A CN201110167220XA CN201110167220A CN102838617A CN 102838617 A CN102838617 A CN 102838617A CN 201110167220X A CN201110167220X A CN 201110167220XA CN 201110167220 A CN201110167220 A CN 201110167220A CN 102838617 A CN102838617 A CN 102838617A
- Authority
- CN
- China
- Prior art keywords
- methyl acetate
- thiophene
- dihydro
- chloro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 239000001301 oxygen Substances 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- NTGRLKONMLOCIZ-UHFFFAOYSA-N 2,3,3a,4-tetrahydrothieno[3,2-b]pyridin-2-ol Chemical class N1C=CC=C2SC(O)CC21 NTGRLKONMLOCIZ-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a polymorph of (S)-2-(2- nicotinoyloxyjatropha-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorphenyl)-methyl acetate and a preparation method and medical applications thereof. A pharmaceutical composition containing the compound disclosed in the invention can be used for preparing medicines for preventing or treating thrombus and thrombotic diseases.
Description
Technical field
The present invention relates to the crystal formation of medical compounds; Be specifically related to a kind of (S)-2-(2-(nicotinylsalicylic oxygen)-6; 7-dihydro-thiophene also [3; 2-c] polymorphic form of pyridine-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate, in addition, the invention also discloses the preparation method and the pharmaceutical composition thereof of this crystal formation thing.
Background technology
The cardiovascular and cerebrovascular thrombotic diseases is a kind of common disease, is that master's the sickness rate of thrombotic disease is in rising trend with crown thrombus and cerebral thrombosis in recent years, and the serious harm human beings'health is therefore, very important to the study on prevention of this type disease.Platelet aggregation is a key link in the normal clotting mechanism, but hematoblastic to stick, assemble also be thrombotic initial link.Therefore, the anticoagulant medicine is being brought into play important effect in the treatment thrombus disease, and the anti-platelet aggregation medicine is the focus that people study always.
The inventor has described in one Chinese patent application 201010104091.5 and 201010624329.7 and has comprised (S)-2-(2-(nicotinylsalicylic oxygen)-6; 7-dihydro-thiophene also [3; 2-c] pyridine-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate has novel 2-hydroxy tetrahydro thienopyridine derivative of anti-platelet aggregation effect and preparation method thereof at interior one type, but above-mentioned patented claim is not described the preparation and the sign of the polymorphic form of title compound free alkali.
The crystal formation of material is the form of material existence, and will inevitably there be different crystal formations in medicine as the material of treatment disease.The crystal formation of medicine can influence the physico-chemical property of material, comprises fusing point, chemicalstability, apparent solubility, dissolution rate, optics and mechanical properties, vp and density.These character can directly influence the processing or the production of bulk drug and preparation, and can influence stability of formulation, solubleness and bioavailability.Therefore, the medicine crystal formation must be the important content of drug research, detection and supervision, also is the important content of drug quality control.
Summary of the invention
(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be a kind of polymorphic form of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate (compound shown by formula I) also to the invention provides (S)-2-.
Another object of the present invention provides a kind of preparation method of formula I compound polymorphic form.
The 3rd purpose of the present invention provides the medicinal compsns that contains above-mentioned formula I compound polymorphic form.
Specifically, the invention provides a kind of polymorphic form A that is substantially free of the formula I compound of other solvents.
The polymorphic form A of formula I compound provided by the present invention; Use the Cu-Ka radiation; Its typical X-x ray diffration pattern x; 2 θ that show with kilsyth basalt have diffraction peak 13.4 ± 0.2,16.1 ± 0.2,18.6 ± 0.2,18.9 ± 0.2 and 19.5 ± 0.2; Particularly; 4.0 ± 0.2,8.5 ± 0.2,9.6 ± 0.2,12.1 ± 0.2,12.5 ± 0.2,14.5 ± 0.2,15.5 ± 0.2,16.6 ± 0.2,20.2 ± 0.2,20.9 ± 0.2,21.6 ± 0.2,21.9 ± 0.2,22.5 ± 0.2,22.8 ± 0.2,23.3 ± 0.2,23.6 ± 0.2,23.9 ± 0.2,24.2 ± 0.2,24.6 ± 0.2,25.1 ± 0.2,25.3 ± 0.2,26.2 ± 0.2,27.3 ± 0.2,27.8 ± 0.2,28.5 ± 0.2,29.4 ± 0.2 one or more (with arbitrary combination, comprising more than two, perhaps whole) diffraction peak is arranged; Especially, at 4.0 ± 0.2,8.5 ± 0.2,9.6 ± 0.2,12.1 ± 0.2,12.5 ± 0.2,13.4 ± 0.2,14.5 ± 0.2,15.5 ± 0.2,16.1 ± 0.2,16.6 ± 0.2,18.6 ± 0.2,18.9 ± 0.2,19.5 ± 0.2,20.2 ± 0.2,20.9 ± 0.2,21.6 ± 0.2,21.9 ± 0.2,22.5 ± 0.2,22.8 ± 0.2,23.3 ± 0.2,23.6 ± 0.2,23.9 ± 0.2,24.2 ± 0.2,24.6 ± 0.2,25.1 ± 0.2,25.3 ± 0.2,26.2 ± 0.2,27.3 ± 0.2,27.8 ± 0.2,28.5 ± 0.2,29.4 ± 0.2 places diffraction peak is arranged.
The polymorphic form A of formula I compound:
In addition, the polymorphic form A of formula I compound of the present invention is characterized by at about 3005cm with the infrared absorption pattern that the KBr compressing tablet records
-1, 2989cm
-1, 2952cm
-1, 1738cm
-1, 1684cm
-1, 1590cm
-1, 1435cm
-1, 1275cm
-1, 1260cm
-1, 1203cm
-1, 766cm
-1, 754cm
-1, 702cm
-1There is absorption peak at the place.
The polymorphic form A of formula I compound provided by the present invention, the maximum endothermic transition of its DSC scanning be about 90 ℃ to 110 ℃, preferably, and about 95 ℃ or 98 ℃.
In embodiments of the invention, the invention provides the preparation method of the polymorphic form A of formula I compound, comprise the steps:
(1) (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene also [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate are dissolved in a kind of solubility organic solvent, again with getting oily matter after the solvent evaporated under reduced pressure with (S)-2-;
(2) add another kind of organic solvent in the oily matter that in step (1), obtains, after stirring or supersound process, separate out solid;
(3) reclaim solid, drying under reduced pressure.
In above-mentioned steps (1), the organic solvent that is adopted is selected from a kind of solvent or the two or more mixed solvents in acetone, methylene dichloride, ETHYLE ACETATE, methyl acetate, n-butyl acetate, acetonitrile, toluene or the THF.
In above-mentioned steps (2), the organic solvent that is adopted is selected from a kind of solvent or the two or more mixed solvents in ethanol, n-propyl alcohol, Virahol, propyl carbinol, the trimethyl carbinol, sec-butyl alcohol, terepthaloyl moietie, ether, isopropyl ether, MTBE, sherwood oil, normal hexane, Skellysolve A or the hexanaphthene.
The present invention also provides the pharmaceutical composition of a kind of prevention or treatment thrombus and embolism relative disease; Wherein contain (S)-2-(2-(nicotinylsalicylic oxygen)-6 that treats significant quantity; The 7-dihydro-thiophene also the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate as active ingredient and pharmaceutically acceptable carrier.Said pharmaceutical composition can be a dosage form conventional on the technology of pharmaceutics such as conventional tablet or capsule, slow releasing tablet or capsule, controlled release tablet or capsule, granule, powder, syrup, oral liquid, injection.
Description of drawings
Fig. 1 is that (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the exemplary x-ray diffracting spectrum of the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-;
Fig. 2 is that (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the IR infrared absorpting light spectra of the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-;
Fig. 3 is that (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the DSC scintigram of the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-;
Fig. 4 is that (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the TGA scintigram of the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-.
Embodiment
Specify content of the present invention through embodiment below.In the present invention, the embodiment of the following stated is in order better to set forth the present invention, is not to be used for limiting scope of the present invention.
(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene also [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate (2.20g) are dissolved in the acetone, remove acetone again under reduced pressure and get colorless oil with (S)-2-.At room temperature, in this oily matter, add 10mL ethanol, under fully stirring, have solid to separate out, continue static crystallization under 3 ℃.The filtering solvent gets filter cake.Filter cake drying under reduced pressure under room temperature gets solid 1.78g, fusing point: 95～97 ℃.This solid is that (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-through X-ray powder diffraction, infrared scan, DSC scanning, TGA scanning conclusive evidence.
(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene also [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate (1.10g) are dissolved in the ETHYLE ACETATE, remove acetone again under reduced pressure and get colorless oil with (S)-2-.At room temperature, in this oily matter, add 10mL ethanol, under fully stirring, have solid to separate out, continue static crystallization under 3 ℃.The filtering solvent gets filter cake.Filter cake drying under reduced pressure under room temperature gets solid 0.75g, fusing point: 95～97 ℃.(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-through the X-ray powder diffraction conclusive evidence for this solid.
(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene also [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate (1.02g) are dissolved in the acetone, and steaming removes acetone and gets colorless oil again with (S)-2-.At room temperature, in this oily matter, add the 10mL MTBE, be statically placed in after the supersound process under the room temperature in 3 ℃ of environment, have solid to separate out.The filtering solvent gets filter cake.Filter cake drying under reduced pressure under room temperature gets pulverulent solids 0.71g, fusing point: 95～97 ℃.(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-through the X-ray powder diffraction conclusive evidence for this solid.
(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene also [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate (1.0g) are dissolved in the acetone, and steaming removes acetone and gets colorless oil again with (S)-2-.At room temperature, in this oily matter, add the 7ml isopropyl ether, be statically placed in after the supersound process in the room temperature environment under the room temperature, separate out solid.The filtering solvent, drying under reduced pressure gets solid 0.70g under room temperature, fusing point: 96～98 ℃.(2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also for (S)-2-through the X-ray powder diffraction conclusive evidence for this solid.
Embodiment 5
Tablet
With (the S)-2-that makes among the embodiment 1 (2-(nicotinylsalicylic oxygen)-6; 7-dihydro-thiophene also [3; 2-c] an amount of and Magnesium Stearate (1g) of the polymorphic form A (50g), HPMC E (150g), starch (200g), 30 POVIDONE K 30 BP/USP 30 of pyridine-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate mixes; Granulate compressing tablet.
Claims (8)
1. (S)-2-(2-(nicotinylsalicylic oxygen)-6; 7-dihydro-thiophene also [3; 2-c] the polymorphic form A of pyridine-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate; Use the Cu-Ka radiation, its x-ray diffraction pattern, 2 θ that show with kilsyth basalt have diffraction peak 13.4 ± 0.2,16.1 ± 0.2,18.6 ± 0.2,18.9 ± 0.2 and 19.5 ± 0.2.
2. (S)-2-according to claim 1 (2-(nicotinylsalicylic oxygen)-6; 7-dihydro-thiophene also [3; 2-c] the polymorphic form A of pyridine-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate; Its x-ray diffraction pattern, 2 θ that show with kilsyth basalt also have one or more diffraction peaks 4.0 ± 0.2,8.5 ± 0.2,9.6 ± 0.2,12.1 ± 0.2,12.5 ± 0.2,14.5 ± 0.2,15.5 ± 0.2,16.6 ± 0.2,20.2 ± 0.2,20.9 ± 0.2,21.6 ± 0.2,21.9 ± 0.2,22.5 ± 0.2,22.8 ± 0.2,23.3 ± 0.2,23.6 ± 0.2,23.9 ± 0.2,24.2 ± 0.2,24.6 ± 0.2,25.1 ± 0.2,25.3 ± 0.2,26.2 ± 0.2,27.3 ± 0.2,27.8 ± 0.2,28.5 ± 0.2,29.4 ± 0.2.
3. (S)-2-according to claim 1 and 2 (2-(nicotinylsalicylic oxygen)-6; The 7-dihydro-thiophene is the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also, and the maximum endothermic transition of its DSC scanning is about 90 ℃ to 110 ℃; Preferably, about 95 ℃ or 98 ℃.
4. (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also, with the infrared absorption pattern that the KBr compressing tablet records, it is characterized by at about 3005cm according to described (the S)-2-of claim 1～3
-1, 2989cm
-1, 2952cm
-1, 1738cm
-1, 1684cm
-1, 1590cm
-1, 1435cm
-1, 1275cm
-1, 1260cm
-1, 1203cm
-1, 766cm
-1, 754cm
-1, 702cm
-1There is absorption peak at the place.
5. (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene be the preparation method of the polymorphic form A of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also, comprises the steps: for described (the S)-2-of claim 1～4
(1) (2-(nicotinylsalicylic oxygen)-6,7-dihydro-thiophene also [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate are dissolved in a kind of solubility organic solvent, again with getting oily matter after the solvent evaporated under reduced pressure with (S)-2-;
(2) add another kind of organic solvent in the oily matter that in step (1), obtains, after stirring or supersound process, separate out solid;
(3) reclaim solid, drying under reduced pressure.
6. the preparation method of claim 5; It is characterized in that the organic solvent that in step (1), is adopted is selected from a kind of solvent or the two or more mixed solvents in acetone, methylene dichloride, ETHYLE ACETATE, methyl acetate, n-butyl acetate, acetonitrile, toluene or the THF; The organic solvent that in step (2), is adopted is selected from a kind of solvent or the two or more mixed solvents in ethanol, n-propyl alcohol, Virahol, propyl carbinol, the trimethyl carbinol, sec-butyl alcohol, terepthaloyl moietie, ether, isopropyl ether, MTBE, sherwood oil, normal hexane, Skellysolve A or the hexanaphthene.
7. the pharmaceutical composition of a prevention or treatment thrombus and embolism relative disease; It is characterized in that; Contain (the 2-(nicotinylsalicylic oxygen)-6 of (S)-2-described in the claim 1～4 in the said pharmaceutical composition; The 7-dihydro-thiophene is the polymorphic form A and the pharmaceutically acceptable carrier of [3,2-c] pyridines-5 (4H)-yl)-2-(2-chloro-phenyl-)-methyl acetate also.
8. pharmaceutical composition as claimed in claim 7 is characterized in that, said pharmaceutical composition is tablet, capsule, slow releasing tablet, granule, powder, syrup, oral liquid or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110167220XA CN102838617A (en) | 2011-06-21 | 2011-06-21 | Polymorph and pharmaceutical composition of (S)-2-(2- nicotinoyloxyjatropha-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorphenyl)-methyl acetate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110167220XA CN102838617A (en) | 2011-06-21 | 2011-06-21 | Polymorph and pharmaceutical composition of (S)-2-(2- nicotinoyloxyjatropha-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorphenyl)-methyl acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102838617A true CN102838617A (en) | 2012-12-26 |
Family
ID=47366370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110167220XA Pending CN102838617A (en) | 2011-06-21 | 2011-06-21 | Polymorph and pharmaceutical composition of (S)-2-(2- nicotinoyloxyjatropha-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorphenyl)-methyl acetate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102838617A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101343278A (en) * | 2007-12-11 | 2009-01-14 | 鲁南制药集团股份有限公司 | Preparation method for hydrogenated pyridine derivant and its salt |
| WO2009130289A1 (en) * | 2008-04-25 | 2009-10-29 | Sandoz Ag | HYDROGENSULFATE SALT OF 2-ACETOXY-5-(a-CYCLOPROPYLCARBONYL-2-FLUOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-c]PYRIDINE AND ITS PREPARATION |
| CN101591344A (en) * | 2008-05-27 | 2009-12-02 | 连云港恒邦医药科技有限公司 | Antithrombotic compound, preparation method and application thereof |
| CN102120744A (en) * | 2010-02-02 | 2011-07-13 | 江苏威凯尔医药科技有限公司 | Optical-activity 2-hydroxytetrahydrothienopyridine derivative, preparation method and application thereof in pharmacy |
-
2011
- 2011-06-21 CN CN201110167220XA patent/CN102838617A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101343278A (en) * | 2007-12-11 | 2009-01-14 | 鲁南制药集团股份有限公司 | Preparation method for hydrogenated pyridine derivant and its salt |
| WO2009130289A1 (en) * | 2008-04-25 | 2009-10-29 | Sandoz Ag | HYDROGENSULFATE SALT OF 2-ACETOXY-5-(a-CYCLOPROPYLCARBONYL-2-FLUOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-c]PYRIDINE AND ITS PREPARATION |
| CN101591344A (en) * | 2008-05-27 | 2009-12-02 | 连云港恒邦医药科技有限公司 | Antithrombotic compound, preparation method and application thereof |
| CN102120744A (en) * | 2010-02-02 | 2011-07-13 | 江苏威凯尔医药科技有限公司 | Optical-activity 2-hydroxytetrahydrothienopyridine derivative, preparation method and application thereof in pharmacy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102265644B1 (en) | Oral formulation of glucokinase activator and method for preparing same | |
| WO2017109041A1 (en) | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant | |
| KR101491729B1 (en) | Composition of stable tiacumicins | |
| CA2916143C (en) | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration | |
| WO2008101723A2 (en) | Pharmaceutical composition containing a cholesterol absorption inhibitor | |
| CN101287463A (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders | |
| EP2398468A1 (en) | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation | |
| EP2714676B1 (en) | A process for the preparation of polymorphic form i of etoricoxib | |
| WO2008001201A2 (en) | Pharmaceutical compositions of clopidogrel | |
| WO2016097030A1 (en) | Pharmaceutical composition comprising amorphous lenalidomide | |
| WO2016097314A1 (en) | Amorphous and crystalline forms of idelalisib and process for forming the same | |
| JP7104039B2 (en) | Pharmaceutical composition | |
| US20200323838A1 (en) | Lenalidomide immediate release formulations | |
| KR20140059146A (en) | Solid dispersions of insoluble drug and preparation method therof | |
| CN102838617A (en) | Polymorph and pharmaceutical composition of (S)-2-(2- nicotinoyloxyjatropha-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)-2-(2-chlorphenyl)-methyl acetate | |
| CN102827184A (en) | Polymorph of 2-hydroxy tetrahydrothienopyridine derivatives and pharmaceutical composition | |
| Rajbhar et al. | Comparative assessment of solubility enhancement of itroconazole by solid dispersion and co-crystallization technique: Investigation of simultaneous effect of media composition on drug dissolution | |
| JP7640453B2 (en) | Pharmaceutical preparations and methods for their manufacture | |
| CN112057427B (en) | Oral solid tablet containing bruton's tyrosine kinase inhibitor and preparation method thereof | |
| CN102775421A (en) | Hydrochloride of 2-hydroxy tetrahydrothienopyridine derivatives, and preparation method and medical application thereof | |
| JP3547009B1 (en) | Novel crystals of 5-[(1Z, 2E) -2-methyl-3-phenyl-2-propenylidene] -4-oxo-2-thioxo-3-thiazolidineacetic acid, a method for producing the same and a drug containing the crystal as an active ingredient | |
| AU2022207756A9 (en) | Solid tablet dosage form of ridinilazole | |
| EP3179987A1 (en) | Pharmaceutical composition of etoricoxib | |
| WO2012023145A2 (en) | Prasugrel hydrochloride crystalline particles | |
| KR100663079B1 (en) | Manufacturing method of solid dispersion containing itraconazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121226 |